Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of
prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate
cancer cells. Together with a PET/CT scanner, the distribution of 68Ga-PSMA can be determined
in the body.
To test this new drug, participants will receive an intravenous injection of Ga-68-PSMA and
then have a PET/CT scan. The scan results will be made available to study participants and
treating physicians.